Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
New research discusses how immunotherapy-related adverse events (irAEs) can impact more than one organ in a single patient.
The pandemic raises new concerns, but it may also lead to long-lasting improvements.
The most aggressive type of skin cancer may respond to immunotherapy.
A Phase 1 study on customized immunotherapy shows promise for people with lung cancer.
A recent clinical trial found that the combination did not work.
Sanda Cohen, 63, a retired physician in Louisville, Kentucky, has lived with Stage IV lung cancer a year longer than she was told she would.
Metastatic kidney cancer patients with greater microbial diversity had better outcomes with immunotherapy.
Stivarga also improved survival in those with recurrent HCC after a liver transplant.
Nearly half of patients treated with the combination saw their tumors shrink in an early study.
Recent studies suggest chemotherapy and immunotherapy are not linked to more severe COVID-19.
Experts provide insights into expanding the effectiveness of new treatments for melanoma.
Tecentriq plus two targeted medications extended progression-free survival by 4.5 months.
The gene-editing tool can alter the DNA of human cells like a precise pair of scissors.
Contrary to what he wrote in his new memoir, the iconic quiz show host plans to continue with treatment indefinitely.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.